NEWS CENTER
Poseida News Center
Featured Content
Read media coverage on Poseida, find resources for the working press, and get insights from our executive leadership team on how Poseida is advancing a new class of cell and gene therapies.
Poseida in the News
FDA Grants Orphan Drug Designation to P-BCMA-ALLO1 in R/R Multiple Myeloma
|
March 14, 2024
A Significant Milestone for the Future of Gene Editing
|
February 28, 2024
Poseida: New CEO, same passion for allogeneic therapies
|
February 26, 2024
Creating CAR T therapies that don’t cause cancer
|
February 16, 2024
4 Keys To Allo In 2024 With Poseida Therapeutics’ Kristin Yarema, Ph.D.
|
January 4, 2024
Roche Partner Poseida Touts High Response Rates for Allogeneic CAR-T Therapy
|
December 11, 2023
Poseida’s soon-to-be CEO on this morning’s allo BCMA CAR-T data at #ASH23
|
December 10, 2023
Approaching The Allogeneic Tipping Point: The Emergence Of Allogeneic Cell Therapy For Oncology
|
November 1, 2023
Executive Perspectives
Press Releases
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
|
March 13, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
|
March 7, 2024
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones
|
January 4, 2024
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
|
December 10, 2023
Media Library
Usage rights & restrictions:
These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.